Sangamo’s STAAR Study Shows Promise in Fabry Disease Treatment
Company Announcements

Sangamo’s STAAR Study Shows Promise in Fabry Disease Treatment

Sangamo Biosciences (SGMO) has released an update.

Sangamo Therapeutics, Inc. has released promising preliminary data from its ongoing Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease. As of September 2023, 24 patients have been treated, showing general tolerability and sustained elevated levels of α-Gal A activity, potentially reducing the need for enzyme replacement therapy (ERT). Moreover, improvements in disease severity and quality of life indices were observed, along with a notable reduction in antibodies associated with ERT. Further dosing and long-term follow-ups are planned, with discussions ongoing with health authorities regarding the path to registration.

For further insights into SGMO stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TipRanks Auto-Generated NewsdeskSangamo Biosciences Positions for Growth with Strategic Shareholder Decisions
TipRanks Auto-Generated NewsdeskSangamo Biosciences: Navigating Biopharma Risks Beyond the Minefield
TheFlySangamo reports Q1 EPS (27c), consensus (21c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!